(Q49069483)

English

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Christina Schaub

1

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Susanne Greschus

2

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Mirko Seifert

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Andreas Waha

4

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Elias Blasius

5

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Katja Rasch

6

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Christiane Landwehr

7

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Frederic Mack

8

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Niklas Schäfer

9

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Moritz Stuplich

10

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Sied Kebir

11

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Belinda Vilz

12

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Björn Scheffler

13

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Jan Boström

14

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Matthias Simon

15

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Horst Urbach

16

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Martin Glas

17

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Ulrich Herrlinger

18

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

publication date

5 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

85

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

191-195

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Bevacizumab does not increase the risk of remote relapse in malignant glioma.

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1159%2F000354692

21 January 2018

Identifiers

10.1159/000354692

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/24008924

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49069483&oldid=2221213044"